| 19.08 0.26 (1.38%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.46 | 1-year : | 26.23 |
| Resists | First : | 19.22 | Second : | 22.46 |
| Pivot price | 16.92 |
|||
| Supports | First : | 16.3 | Second : | 14.5 |
| MAs | MA(5) : | 18.68 |
MA(20) : | 16.8 |
| MA(100) : | 17.84 |
MA(250) : | 18.6  |
|
| MACD | MACD : | 0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 94.6 |
D(3) : | 94.5 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 24.98 | Low : | 13.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRTC ] has closed below upper band by 14.2%. Bollinger Bands are 106.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.1 - 19.18 | 19.18 - 19.24 |
| Low: | 18.57 - 18.66 | 18.66 - 18.74 |
| Close: | 18.92 - 19.07 | 19.07 - 19.2 |
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Mon, 29 Sep 2025
PureTech's Deupirfenidone Shows 91mL Lung Function Benefit in IPF Trial | PRTC Stock News - Stock Titan
Tue, 23 Sep 2025
Recent uptick might appease PureTech Health plc (LON:PRTC) institutional owners after losing 12% over the past year - simplywall.st
Tue, 16 Sep 2025
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
Mon, 15 Sep 2025
PureTech Health announces CEO transition - MSN
Thu, 28 Aug 2025
PureTech Health plc – Half-Year Report 2025 - BioSpace
Thu, 21 Aug 2025
PureTech Health Advances Deupirfenidone in IPF Treatment - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.6683e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1572e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 792.9 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 589.5 % |
| Return on Equity (ttm) | -13 % |
| Qtrly Rev. Growth | 6.39e+006 % |
| Gross Profit (p.s.) | 670 |
| Sales Per Share | 11.65 |
| EBITDA (p.s.) | -6.02593e+007 |
| Qtrly Earnings Growth | 1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.63 |
| Price to Cash Flow | 9.84 |
| Dividend | 0 |
| Forward Dividend | 6500 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2025-03-24 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|